Answers are grounded in this paper and cite their sources.
Pancreatic ductal adenocarcinoma (PDAC) remains difficult to treat because of late diagnosis, desmoplasia, and multiple mechanisms of therapeutic resistance. Extracellular vesicle (EV)-associated microRNAs (miRNAs) have been implicated in communication between PDAC cells and stromal or immune populations. This mini review critically distinguishes three levels of evidence: functional delivery of EV-associated miRNAs to recipient cells, associations between vesicle-associated miRNAs and clinical phenotypes, and non-vesicular or intracellular miRNA observations that provide contextual but not direct evidence of EV-mediated effects. Mechanistic studies implicate stromal miR-21 and miR-106b, tumour-associated miR-155 and miR-210, hypoxia-associated miR-301a and miR-30b-5p, and miR-212-3p in tumour–microenvironment interactions or treatment-related phenotypes, although the strength of causal transfer evidence varies. Plasma, serum and salivary EV-miRNA signatures are being explored for liquid biopsy, but they require prospective validation. Engineered EV-mediated siRNA delivery has reached early clinical evaluation in PDAC; this must not be conflated with clinical validation of EV-based miRNA therapeutics. We integrate mechanistic, biomarker and delivery evidence, emphasizing EV nomenclature, functional-transfer controls, and translational limitations.
No takes yet. Share an insight, caveat, or question.
Ang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: